Kilitch Drugs (India) Ltd
ROE vs FD ratesFixed Deposit rate is a virtually risk-free rate where the investor assumes almost no risk on their investment. If stock's long term average ROE is lower than this rate, investors are better off investing the amount in a FD
Stock has not been able to generate better return on equity than bank FD
Dividend ReturnsA dividend is the distribution of reward from a portion of company's earnings and is paid to its shareholders. Good dividend returns indicate good health and outlook for the company
Stock doesn't offer attractive dividend returns
Entry PointHigh demand for a stock increases its price. If the price is pushed up to a level which is not justified, then it's considered to be in the overbought zone, which is not a good time to buy the stock
Good time to consider, as stock is not in overbought zone
No Red FlagsASM and GSM lists are measures to safeguard investors against volatility and unjustified stock prices. Pledging holdings means taking loans against held promoter shares. Stocks in ASM/GSM list or with high pledged promoter holding should be handled with caution. Unsolicited tips are sometimes circulated to manipulate the market. Beware of these stocks
Stock not in ASM/GSM lists and not a lot of promoter holding is pledged
Kilitch Drugs (India) Ltd
KILITCH
Intrinsic ValueIntrinsic value is the calculated value of the company and may differ from current stock price. If intrinsic value > current price, price increase is expected in the future to reduce the gap and vice-versa
Current price is more than the intrinsic value
ROE vs FD ratesFixed Deposit rate is a virtually risk-free rate where the investor assumes almost no risk on their investment. If stock's long term average ROE is lower than this rate, investors are better off investing the amount in a FD
Stock has not been able to generate better return on equity than bank FD
Dividend ReturnsA dividend is the distribution of reward from a portion of company's earnings and is paid to its shareholders. Good dividend returns indicate good health and outlook for the company
Stock doesn't offer attractive dividend returns
Entry PointHigh demand for a stock increases its price. If the price is pushed up to a level which is not justified, then it's considered to be in the overbought zone, which is not a good time to buy the stock
Good time to consider, as stock is not in overbought zone
No Red FlagsASM and GSM lists are measures to safeguard investors against volatility and unjustified stock prices. Pledging holdings means taking loans against held promoter shares. Stocks in ASM/GSM list or with high pledged promoter holding should be handled with caution. Unsolicited tips are sometimes circulated to manipulate the market. Beware of these stocks
Stock not in ASM/GSM lists and not a lot of promoter holding is pledged
Key Metrics
| PE RatioPE Ratio | PB RatioPB Ratio | Dividend YieldDiv. Yield |
|---|---|---|
| 24.02 | 1.42 | — |
| Sector PESector PE | Sector PBSector PB | Sector Div YldSctr Div Yld |
|---|---|---|
| 35.90 | 4.36 | 0.88% |
Forecast & RatingsDetailed Forecast
Analysts have suggested that investors can buy this stock
Price
Price Upside
Earnings
Earnings Growth
Revenue
Rev. Growth
Company Profile
Kilitch Drugs (India) Limited is an India-based company, which is engaged in the development and operations of its pharmaceutical business. The Company primarily offers ONECEF INJ.1GM and KILITCH SRO 20.80GMS. The Company's parenteral solutions include Hyoce, Metoclop, K-Suxa, Kytoin, Artim, Neticin, Klavmox, Kilox, Clinda, Flork, Adron, Pivac, Ergomet, Kilmeta, Zovikil, Bivadin, Dexo, Dokine, Kain, K-Fol, Kiol, Vankom, Kabalin, Chlorpheniramine, Mectin, Cybuta, Onecef, Carboplatin Injection, Paclitaxel Injection, Snake Venom Antiserum (Lyophilized), Gas Gangrene and Carboxymethylcellulose Sodium Ophthalmic solution. Its effervescent products include ROIPAR, DUREGRA and ROIVIT. The Company's nutritional product range includes Celtine. The Company offers medical devices, such as C-Seal. The Company offers products for various categories, such as gastroenterology, non-steroidal anti-inflammatory drugs, anticonvulsant/antiepileptic, anti-inflammatory, anti-malarials and aminoglycosides.
PeersCompare with peers
Sun Pharmaceutical Industries Ltd
Cipla Ltd
Dr Reddy's Laboratories Ltd
Torrent Pharmaceuticals Ltd
Abbott India Ltd
Get more out of Tickertape, Go Pro!
Customise key metrics, see detailed forecasts, download stock data and more
Holdings TrendDetailed holdings
Total Promoter HoldingIncreasing promoter holding is considered good and reflects management’s positive view about the future outlook
In last 6 months, promoter holding in the company has almost stayed constant
Low Pledged Promoter HoldingLower pledged promoter holdings is considered better
Pledged promoter holdings is insignificant
Mutual Fund HoldingIncreasing Mutual Fund holdings are generally considered good, as it reflects that fund managers are becoming more bullish about the stock
In last 3 months, mutual fund holding of the company has almost stayed constant
Recent NewsAll news
Hmm, looks like data is unavailable here. Please come back after some timeRecent EventsAll events
Newspaper Advertisements
Newspaper publication pertaining to the extract of the financial results of the Company for the quarter ended 30th September, 2022. The said extract of the financial results was published on Marathi and English edition on 15th November, 2022. | Download
Newspaper publication pertaining to the extract of the financial results of the Company for the quarter ended 30th September, 2022. The said extract of the financial results was published on Marathi and English edition on 15th November, 2022. | Download
Outcome of Board Meeting
Kilitch Drugs (India) Limited has informed the Exchange about Board Meeting held on 14-Nov-2022 to consider financial statements for the period ended September 2022 | Download
Kilitch Drugs (India) Limited has informed the Exchange about Board Meeting held on 14-Nov-2022 to consider financial statements for the period ended September 2022 | Download
Cash Dividend
Final • Div/Share: ₹ 0.5
Intrinsic ValueIntrinsic value is the calculated value of the company and may differ from current stock price. If intrinsic value > current price, price increase is expected in the future to reduce the gap and vice-versa
Current price is more than the intrinsic value